Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5637685, 12 pages
http://dx.doi.org/10.1155/2016/5637685
Research Article

Exaggerated IL-15 and Altered Expression of foxp3+ Cell-Derived Cytokines Contribute to Enhanced Colitis in Nlrp3−/− Mice

1Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada T2N 4N1
2Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, AB, Canada T2N 4N1
3Department of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1
4Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, AB, Canada T2N 4N1

Received 1 April 2016; Accepted 28 July 2016

Academic Editor: Ronald Gladue

Copyright © 2016 Simon A. Hirota et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Xavier and D. K. Podolsky, “Unravelling the pathogenesis of inflammatory bowel disease,” Nature, vol. 448, no. 7152, pp. 427–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Cario, “Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond,” Current Opinion in Gastroenterology, vol. 26, no. 6, pp. 583–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. C. Villani, M. Lemire, G. Fortin et al., “Common variants in the NLRP3 region contribute to Crohn's disease susceptibility,” Nature Genetics, vol. 41, pp. 71–76, 2009. View at Google Scholar
  4. A.-C. Villani, M. Lemire, E. Louis et al., “Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis,” PLoS ONE, vol. 4, no. 9, Article ID e7154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Pétrilli, C. Dostert, D. A. Muruve, and J. Tschopp, “The inflammasome: a danger sensing complex triggering innate immunity,” Current Opinion in Immunology, vol. 19, no. 6, pp. 615–622, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Hirota, J. Ng, A. Lueng et al., “NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis,” Inflammatory Bowel Diseases, vol. 17, no. 6, pp. 1359–1372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. H. Zaki, M. Lamkanfi, and T.-D. Kanneganti, “The Nlrp3 inflammasome: contributions to intestinal homeostasis,” Trends in Immunology, vol. 32, no. 4, pp. 171–179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. I. C. Allen, E. M. Tekippe, R.-M. T. Woodford et al., “The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer,” The Journal of Experimental Medicine, vol. 207, no. 5, pp. 1045–1056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Hu, C. Xu, and J. L. Staudinger, “Pregnane X receptor is SUMOylated to repress the inflammatory response,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 2, pp. 342–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Biswas, D. Pasquel, R. K. Tyagi, and S. Mani, “Acetylation of pregnane X receptor protein determines selective function independent of ligand activation,” Biochemical and Biophysical Research Communications, vol. 406, no. 3, pp. 371–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Staudinger, C. Xu, A. Biswas, and S. Mani, “Post-translational modification of pregnane x receptor,” Pharmacological Research, vol. 64, no. 1, pp. 4–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Y. Cui, S. S. Gunewardena, C. E. Rockwell, and C. D. Klaassen, “ChIPing the cistrome of PXR in mouse liver,” Nucleic Acids Research, vol. 38, no. 22, pp. 7943–7963, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Gupta, M. Venkatesh, H. Wang et al., “Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer,” Clinical Cancer Research, vol. 14, no. 17, pp. 5332–5340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Wang, I. Damjanov, and Y.-J. Y. Wan, “The protective role of pregnane X receptor in lipopolysaccharide/D-galactosamine-induced acute liver injury,” Laboratory Investigation, vol. 90, no. 2, pp. 257–265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. L. Staudinger, X. Ding, and K. Lichti, “Pregnane X receptor and natural products: beyond drug-drug interactions,” Expert Opinion on Drug Metabolism & Toxicology, vol. 2, no. 6, pp. 847–857, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Hirota, S. A. Hirota, S. M. Warner et al., “The airway epithelium nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome is activated by urban particulate matter,” Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 1116–1125.e6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Barnes and F. Powrie, “Regulatory T cells reinforce intestinal homeostasis,” Immunity, vol. 31, no. 3, pp. 401–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Eastaff-Leung, N. Mabarrack, A. Barbour, A. Cummins, and S. Barry, “Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease,” Journal of Clinical Immunology, vol. 30, no. 1, pp. 80–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. W. Kim, E. S. Kim, C. M. Moon et al., “Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease,” Gut, vol. 60, no. 11, pp. 1527–1536, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Sarra, F. Pallone, T. T. MacDonald, and G. Monteleone, “IL-23/IL-17 axis in IBD,” Inflammatory Bowel Diseases, vol. 16, no. 10, pp. 1808–1813, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ziolkowska, A. Koc, G. Luszczykiewicz et al., “High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism,” The Journal of Immunology, vol. 164, no. 5, pp. 2832–2838, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. H. J. P. M. Koenen, R. L. Smeets, P. M. Vink, E. Van Rijssen, A. M. H. Boots, and I. Joosten, “Human CD25highFoxp3pos regulatory T cells differentiate into IL-17 producing cells,” Blood, vol. 112, no. 6, pp. 2340–2352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Diaz-Granados, K. Howe, J. Lu, and D. M. McKay, “Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity,” American Journal of Pathology, vol. 156, no. 6, pp. 2169–2177, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. P. L. Beck, Y. Li, J. Wong et al., “Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation,” Gastroenterology, vol. 132, no. 5, pp. 1778–1790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. K. Watkins, B. Li, K. S. Richardson et al., “Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression,” European Journal of Immunology, vol. 39, no. 8, pp. 2126–2135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Hovhannisyan, J. Treatman, D. R. Littman, and L. Mayer, “Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 3, pp. 957–965, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Ueno, H. Jijon, R. Chan et al., “Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients,” Inflammatory Bowel Diseases, vol. 19, no. 12, pp. 2522–2534, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Ferretti, O. Bonneau, G. R. Dubois, C. E. Jones, and A. Trifilieff, “Il-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger,” The Journal of Immunology, vol. 170, no. 4, pp. 2106–2112, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. R. W. Depaolo, V. Abadie, F. Tang et al., “Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens,” Nature, vol. 471, no. 7337, pp. 220–225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Ahmadzadeh, P. A. Antony, and S. A. Rosenberg, “IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells,” Journal of Immunotherapy, vol. 30, no. 3, pp. 294–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Asanuma, J. Tanaka, J. Sugita et al., “Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin,” Annals of Hematology, vol. 90, no. 6, pp. 617–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Dupaul-Chicoine, G. Yeretssian, K. Doiron et al., “Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases,” Immunity, vol. 32, no. 3, pp. 367–378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. H. Zaki, P. Vogel, M. Body-Malapel, M. Lamkanfi, and T.-D. Kanneganti, “IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation,” Journal of Immunology, vol. 185, no. 8, pp. 4912–4920, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Lodolce, P. Burkett, R. Koka et al., “Interleukin-15 and the regulation of lymphoid homeostasis,” Molecular Immunology, vol. 39, no. 9, pp. 537–544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. I. B. McInnes and J. A. Gracie, “Interleukin-15: a new cytokine target for the treatment of inflammatory diseases,” Current Opinion in Pharmacology, vol. 4, no. 4, pp. 392–397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. S. A. Kliewer, B. Goodwin, and T. M. Willson, “The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism,” Endocrine Reviews, vol. 23, no. 5, pp. 687–702, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. S. A. Kliewer and T. M. Willson, “Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor,” Journal of Lipid Research, vol. 43, no. 3, pp. 359–364, 2002. View at Google Scholar · View at Scopus
  39. D. R. Schmidt and D. J. Mangelsdorf, “Nuclear receptors of the enteric tract: guarding the frontier,” Nutrition Reviews, vol. 66, no. 2, pp. S88–S97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Wang, X. Wang, J. Chun et al., “Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium,” The Journal of Immunology, vol. 190, no. 3, pp. 1239–1249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Kirman and O. H. Nielsen, “Increased numbers of interleukin-15-expressing cells in active ulcerative colitis,” The American Journal of Gastroenterology, vol. 91, no. 9, pp. 1789–1794, 1996. View at Google Scholar · View at Scopus
  42. G. Bouchaud, E. Mortier, M. Flamant et al., “Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease,” Gastroenterology, vol. 138, no. 7, pp. 2378–2387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Takekawa, Y. Kubota, T. Nakamura, and K. Ichikawa, “Regulation of stress-activated MAP kinase pathways during cell fate decisions,” Nagoya Journal of Medical Science, vol. 73, no. 1-2, pp. 1–14, 2011. View at Google Scholar · View at Scopus
  44. K. Yoshihara, T. Yajima, C. Kubo, and Y. Yoshikai, “Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice,” Gut, vol. 55, no. 3, pp. 334–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Yokoyama, N. Watanabe, N. Sato et al., “Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15849–15854, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Obermeier, M. Hausmann, S. Kellermeier et al., “IL-15 protects intestinal epithelial cells,” European Journal of Immunology, vol. 36, no. 10, pp. 2691–2699, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Badoual, G. Bouchaud, N. E. H. Agueznay et al., “The soluble α chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer,” Cancer Research, vol. 68, no. 10, pp. 3907–3914, 2008. View at Publisher · View at Google Scholar · View at Scopus